Primary malignant neoplasm
|
|
0.020 |
GeneticVariation
|
BEFREE |
Patients with CASP9 (rs1052576) CT genotype were 12.8 fold higher in pathological stage of pT2a compared to any other stages of cancer (OR=0.078, 95% CI= 0.009-0.062; p=0.004).
|
28358701 |
2017 |
Malignant Neoplasms
|
|
0.020 |
GeneticVariation
|
BEFREE |
Patients with CASP9 (rs1052576) CT genotype were 12.8 fold higher in pathological stage of pT2a compared to any other stages of cancer (OR=0.078, 95% CI= 0.009-0.062; p=0.004).
|
28358701 |
2017 |
Primary malignant neoplasm
|
|
0.020 |
GeneticVariation
|
BEFREE |
However, the rs1052576 A allele, rs1052576 A carrier, rs2308941 T allele, and rs2308941 T carrier might decrease the risk of cancer (OR = 0.72, 95%CI = 0.58-0.89, P = 0.003; OR = 0.76, 95%CI = 0.63-0.92, P = 0.004; OR = 0.20, 95%CI = 0.09-0.45, P < 0.0001; OR = 0.21, 95%CI = 0.06-0.75, P = 0.02, respectively).
|
23479167 |
2013 |
Malignant Neoplasms
|
|
0.020 |
GeneticVariation
|
BEFREE |
However, the rs1052576 A allele, rs1052576 A carrier, rs2308941 T allele, and rs2308941 T carrier might decrease the risk of cancer (OR = 0.72, 95%CI = 0.58-0.89, P = 0.003; OR = 0.76, 95%CI = 0.63-0.92, P = 0.004; OR = 0.20, 95%CI = 0.09-0.45, P < 0.0001; OR = 0.21, 95%CI = 0.06-0.75, P = 0.02, respectively).
|
23479167 |
2013 |
Brain Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
CASP-9 (rs1052576) mutant A allele seems to be a protective factor for glioma brain tumor.
|
28870924 |
2017 |
Brain Tumor, Primary
|
|
0.010 |
GeneticVariation
|
BEFREE |
Role of Caspase-9 Gene Ex5+32 G>A (rs1052576) Variant in Susceptibility to Primary Brain Tumors.
|
28870924 |
2017 |
Malignant neoplasm of prostate
|
|
0.010 |
GeneticVariation
|
BEFREE |
CASP9 (rs1052576) C allele was decreasing the risk for pathological stage of patients with prostate cancer and also CT genotype had positive impact on pathological stage of patients with prostate cancer.
|
28358701 |
2017 |
Glioma
|
|
0.010 |
GeneticVariation
|
BEFREE |
CASP-9 (rs1052576) mutant A allele seems to be a protective factor for glioma brain tumor.
|
28870924 |
2017 |
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
CASP9 (rs1052576) C allele was decreasing the risk for pathological stage of patients with prostate cancer and also CT genotype had positive impact on pathological stage of patients with prostate cancer.
|
28358701 |
2017 |
Leukemia, Myelocytic, Acute
|
|
0.010 |
GeneticVariation
|
BEFREE |
To test this hypothesis, we have analyzed four CASP9 gene polymorphisms [CASP9 - 1263A > G (rs4645978), CASP9 - 712C > T (rs4645981), CASP9 - 293_275del CGTGAGGTC AGTGCGGGGA (-293del) (rs4645982), and CASP9 Ex5 + 32G > A (rs1052576)] in 180 AML cases and 304 age- and sex-matched healthy controls.
|
24879622 |
2014 |
Lymphoma, Non-Hodgkin
|
|
0.010 |
GeneticVariation
|
BEFREE |
We investigated five single nucleotide polymorphisms in four key caspase genes, CASP3 [Ex8-280C>A (rs6948) and Ex8+567T>C (rs1049216)], CASP8 Ex14-271A>T (rs13113), CASP9 Ex5+32G>A (rs1052576) and CASP10 Ex3-171A>G (rs3900115) to determine whether they alter risk for non-Hodgkin lymphoma (NHL) in a population-based case-control study of women in Connecticut (461 cases and 535 controls).
|
17071630 |
2007 |